(Reuters) - Sanofi SA, whose top-selling Lantus helps diabetics control blood sugar levels, has filed a lawsuit accusing Eli Lilly and Co of infringing seven patents related to insulin and devices ...
The US Court of Appeals for the First Circuit last week ruled that Sanofi improperly submitted a patent for its insulin device in the US Food and Drug Administration’s (FDA) Orange Book and could ...
LONDON, June 29 (Reuters) - Sanofi-Aventis's diabetes drug Lantus may increase the risk of cancer, according to new but inconclusive studies from experts around Europe. Shares in the French drugmaker ...
(RTTNews) - Sandoz Group AG (SDZ.SW) announced that the European Commission has approved Ondibta (insulin glargine), a biosimilar to Sanofi's Lantus SoloStar, for the treatment of diabetes mellitus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results